Inozyme Pharma, Inc. (INZY) Financials

INZY Assets vs Liabilities

DateAssetsLiabilities
Dec. 31, 2023 200.8 million 60.4 million
Sept. 30, 2023 205.7 million 45.5 million
June 30, 2023 150.9 million 45.3 million
March 31, 2023 141.8 million 38.4 million

INZY Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2023 -18.6 million 1.7 million
Sept. 30, 2023 -18.9 million 1.7 million
June 30, 2023 -15.6 million 1.6 million
March 31, 2023 -17.9 million 2.1 million

INZY Net Income

No data available :(

INZY Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2023 188.6 million - 1.8 million
Sept. 30, 2023 192.4 million - 2.0 million
June 30, 2023 140.2 million 31.9 million 2.2 million
March 31, 2023 130.9 million 24.2 million 2.4 million

INZY Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2023 61.8 million
Sept. 30, 2023 56.8 million
June 30, 2023 44.9 million
March 31, 2023 43.7 million

INZY Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2023 105000 17.8 million 4.8 million 130000
Sept. 30, 2023 7000 13.3 million 4.7 million -
June 30, 2023 11000 11.7 million 4.7 million -
March 31, 2023 175000 11.9 million 6.5 million -

INZY Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2023 - 306000
Sept. 30, 2023 - 333000
June 30, 2023 - 331000
March 31, 2023 - 324000

INZY

Price: $4

52 week price:
0.72
6.24

Earnings Per Share: -1.68 USD

P/E Ratio: -2.38

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 94105

Market Capitalization: 258.2 million

Links: